All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1908P"
1908P - FGFR1-4 mutations are associated with immunotherapy outcomes in patients with non-small cell lung cancer
- Ji Chen (Shanghai, China)
Abstract
Background
Non-small cell lung cancer has entered the era of immune checkpoint inhibitor treatments. However, some cancer patients can benefit from immunotherapy, while some others cannot. In addition to PD-L1 expression, previous studies have found that genetic variations are also correlated with immunotherapy efficacy. For example, EGRF, ALK and STK11 mutations are associated with poorer efficacy, while KRAS and TP53 are associated with better efficacy. In clinical practice, we have found that some patients who benefit from immunotherapy have common FGFR1-4 mutations. We further validated this finding in five public cohort study data.
Methods
A total of five independent cancer cohorts (Rizvi cohort 34, Rizvi cohort 240, Zhang cohort, Van Allen cohort, MSKCC cohort) were included for analysis. The clinical outcomes including progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meier curves and log-rank test was used to compare the differences between curves with hazard ratio (HR) determined by univariable Cox regression in R 3.5.2 and IBM SPSS Statistic 21. The TCGA cohort was used for prognostic analysis.
Results
These five independent cancer cohorts uncovered marked correlation between FGFR1-4 mutations and better immunotherapy outcomes in NSCLC population. Median progression-free survival was 13.2 months (95% CI, 9.1 to 17.3) in the FGFR1-4 mutations group and 3.8 months in the FGFR1-4 wild-type group (95% CI, 3.1 to 4.4) (hazard ratio for disease progression or death, 0.43; 95% CI, 0.30 to 0.62; P=0.0007). Median overall survival was 19.8 months (95% CI, 13.4 to 24.6) in the FGFR1-4 mutations group and 11.0 months (95% CI, 9.1 to 13.0) in the FGFR wild-type group (hazard ratio for death, 0.56; 95% CI, 0.36 to 0.89; P=0.03).
Conclusions
This work provides FGFR1-4 as a potential predictor to favorable immunotherapy outcomes in NSCLC, highlighting the importance of genomic profiling in mutations before immunotherapy applications which may provide clue for future clinical practice.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.